Svatek RS - Search Results

1

Predictors of survival in patients with soft tissue surgical margin involvement at radical cystectomy.

Xylinas E, Rink M, Novara G, Green DA, Clozel T, Fritsche HM, Guillonneau B, Lotan Y, Kassouf W, Tilki D, Babjuk M, Karakiewicz PI, Montorsi F, Abdennabi J, Trinh QD, Svatek RS, Scherr DS, Zerbib M, Shariat SF. Xylinas E, et al. Among authors: svatek rs. Ann Surg Oncol. 2013 Mar;20(3):1027-34. doi: 10.1245/s10434-012-2708-5. Epub 2012 Oct 26. Ann Surg Oncol. 2013. PMID: 23099729

2

Correlation of office-based cystoscopy and cytology with histologic diagnosis: how good is the reference standard?

Svatek RS, Lee D, Lotan Y. Svatek RS, et al. Urology. 2005 Jul;66(1):65-8. doi: 10.1016/j.urology.2005.02.003. Urology. 2005. PMID: 15992876

3

Pre-treatment nomogram for disease-specific survival of patients with chemotherapy-naive androgen independent prostate cancer.

Svatek R, Karakiewicz PI, Shulman M, Karam J, Perrotte P, Benaim E. Svatek R, et al. Eur Urol. 2006 Apr;49(4):666-74. doi: 10.1016/j.eururo.2005.11.032. Epub 2006 Jan 6. Eur Urol. 2006. PMID: 16423446

4

Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.

Svatek RS, Herman MP, Lotan Y, Casella R, Hsieh JT, Sagalowsky AI, Shariat SF. Svatek RS, et al. Cancer. 2006 Apr 15;106(8):1701-7. doi: 10.1002/cncr.21795. Cancer. 2006. PMID: 16541433 Free article.

5

Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis.

Svatek RS, Sagalowsky AI, Lotan Y. Svatek RS, et al. Urol Oncol. 2006 Jul-Aug;24(4):338-43. doi: 10.1016/j.urolonc.2005.11.025. Urol Oncol. 2006. PMID: 16818188

6

Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis.

Lotan Y, Svatek RS, Sagalowsky AI. Lotan Y, et al. Among authors: svatek rs. Cancer. 2006 Sep 1;107(5):982-90. doi: 10.1002/cncr.22084. Cancer. 2006. PMID: 16862567 Free article.

7

The cost of prostate cancer chemoprevention: a decision analysis model.

Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y. Svatek RS, et al. Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1485-9. doi: 10.1158/1055-9965.EPI-06-0221. Cancer Epidemiol Biomarkers Prev. 2006. PMID: 16896037

8

The influence of clinical and pathological stage discrepancy on cancer specific survival in patients treated for renal cell carcinoma.

Svatek RS, Lotan Y, Herman MP, Duchene DA, Sagalowsky AI, Cadeddu JA. Svatek RS, et al. J Urol. 2006 Oct;176(4 Pt 1):1321-5; discussion 125. doi: 10.1016/j.juro.2006.06.008. J Urol. 2006. PMID: 16952621

9

Intermediate comparison of partial nephrectomy and radiofrequency ablation for clinical T1a renal tumours.

Stern JM, Svatek R, Park S, Hermann M, Lotan Y, Sagalowsky AI, Cadeddu JA. Stern JM, et al. BJU Int. 2007 Aug;100(2):287-90. doi: 10.1111/j.1464-410X.2007.06937.x. BJU Int. 2007. PMID: 17617136

10

Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy.

Shariat SF, Svatek RS, Kabbani W, Walz J, Lotan Y, Karakiewicz PI, Roehrborn CG. Shariat SF, et al. Among authors: svatek rs. BJU Int. 2008 Jan;101(2):232-7. doi: 10.1111/j.1464-410X.2007.07181.x. Epub 2007 Sep 13. BJU Int. 2008. PMID: 17868422

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

207 results

Search Page

Filters